Vericel Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
Vericel Stock Forecast and Price Target
Vericel's stock is projected to advance by 18.86% from the previous closing price if it reaches the average target of $53.00 by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $54.00 and a low-end estimate of $47.40. If you're interested in VCEL stock, it's important to compare it to other companies in the industry.
18.86% Upside
Vericel Fair Value Forecast for 2023 - 2025 - 2030
Vericel's Price has decreased by 100.00% In the last four years, from $1.45 to $0.00. For the next year, analysts are expecting Fair Value to reach $48.38 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$355.59 | Buy/Sell | $353.16 | 1.38% |
ZBH Stock Forecast | Zimmer Biomet Holdings | Hold |
15
|
$128.04 | Buy/Sell | $132.52 | 5.44% |
IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$36.22 | Buy/Sell | $46.60 | 20.10% |
CNMD Stock Forecast | CONMED | Outperform |
16
|
$84.90 | Buy/Sell | $123.38 | 26.62% |
MDXG Stock Forecast | MiMedx Group | Buy |
6
|
$8.00 | Buy/Sell | $11.85 | 50.00% |
Vericel Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Vericel's Revenue has grown by 59.06%, from $124.18M to $197.52M. For the next year, analysts are expecting Revenue to reach $239.97M – an increase of 21.49%. Over the next seven years, experts predict that Revenue will grow by 311.72%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$14.30 | Buy/Sell | $18.00 | 4.90% |
ORGO Stock Forecast | Organogenesis Holdings | Outperform |
10
|
$2.98 | Buy/Sell | $4.75 | 67.79% |
RCEL Stock Forecast | AVITA Medical | Buy |
6
|
$16.44 | Buy/Sell | $37.39 | 132.85% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ANIK Stock Forecast | Anika Therapeutics | Outperform |
10
|
$25.79 | Buy/Sell | $27.33 | 12.45% |
ATE Stock Forecast | Antibe Therapeutics | Hold |
-10
|
C$0.43 | Buy/Sell | C$1.69 | 248.84% |
BRTX Stock Forecast | BioRestorative Therapies | Outperform |
0
|
$1.28 | Buy/Sell | $15.00 | 876.56% |
Vericel EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Vericel's EBITDA has decreased by 138.45%, from $4.76M to $-1.83M. For the next year, 4 analysts project Vericel's EBITDA to drop by 2614.21%, reaching $46.01M. By 2030, professionals believe that Vericel's EBITDA will decrease by 14275.96%, reaching $259.42M – a concerning trend for the company.
Vericel EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Vericel's EBIT has fallen from $2.37M to $-6.46M – a 372.57% decrease. According to 3 prominent analysts, Vericel's EBIT will fall by 198.14% in the next year, reaching $6.34M. By 2030, professionals believe that Vericel's EBIT will decrease by 3343.96%, reaching $209.56M – a concerning trend for the company.
Vericel EPS Price Prediction Forecast for 2023 - 2025 - 2030
Vericel's EPS has decreased by 100.00% In the last four years, from $0.06 to $0.00. For the next year, analysts are expecting EPS to reach $0.15 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.